Key facts
- This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for Celcuity Inc. (CELC).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 16 Jul 2026, 17:42.
BAKER BROS. ADVISORS LP - 14 Jul 2026 Form 4 Insider Report for Celcuity Inc. (CELC)
- Reporting relationship
- Former 10% owner
- Issuer ticker
- CELC
- Reported as of
- 14 Jul 2026
- Net transaction value
- -$317,750,000
- SEC form
- 4
- Accepted by SEC
- 16 Jul 2026, 17:42:18 UTC
- Prior SEC filing
- 02 Jul 2026
- Next SEC filing
- 11 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
BAKER BROS. ADVISORS LP filed Form 4 for Celcuity Inc. (CELC) on 16 Jul 2026.
Change
- Previous filing in this sequence was filed on 02 Jul 2026.
- Current net transaction value: -$317,750,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (4)
CIK 0001263508
Primary reporting owner
BAKER BROS. ADVISORS LP
- Relationship
- Former 10% owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
- Signature date
- 16 Jul 2026
CIK 0001580575
Baker Bros. Advisors (GP) LLC
- Relationship
- Former 10% owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
- Signature date
- 16 Jul 2026
CIK 0001087940
BAKER FELIX
- Relationship
- Former 10% owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- /s/ Felix J. Baker
- Signature date
- 16 Jul 2026
CIK 0001087939
BAKER JULIAN
- Relationship
- Former 10% owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- /s/ Julian C. Baker
- Signature date
- 16 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CELC
transaction
Common Stock
Sale
- Transaction value
- $26,790,220
- Shares
- -261,368
- Change %
- -37%
- Price
- $102.50
- Shares after
- 442,940
- Date
- 14 Jul 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
CELC
transaction
Common Stock
Sale
- Transaction value
- $26,790,220
- Shares
- -261,368
- Change %
- -37%
- Price
- $102.50
- Shares after
- 442,940
- Date
- 14 Jul 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
CELC
transaction
Common Stock
Sale
- Transaction value
- $26,790,220
- Shares
- -261,368
- Change %
- -37%
- Price
- $102.50
- Shares after
- 442,940
- Date
- 14 Jul 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
CELC
transaction
Common Stock
Sale
- Transaction value
- $26,790,220
- Shares
- -261,368
- Change %
- -37%
- Price
- $102.50
- Shares after
- 442,940
- Date
- 14 Jul 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
CELC
transaction
Common Stock
Sale
- Transaction value
- $290,959,780
- Shares
- -2,838,632
- Change %
- -39%
- Price
- $102.50
- Shares after
- 4,372,852
- Date
- 14 Jul 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3, F4
CELC
transaction
Common Stock
Sale
- Transaction value
- $290,959,780
- Shares
- -2,838,632
- Change %
- -39%
- Price
- $102.50
- Shares after
- 4,372,852
- Date
- 14 Jul 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3, F4
CELC
transaction
Common Stock
Sale
- Transaction value
- $290,959,780
- Shares
- -2,838,632
- Change %
- -39%
- Price
- $102.50
- Shares after
- 4,372,852
- Date
- 14 Jul 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3, F4
CELC
transaction
Common Stock
Sale
- Transaction value
- $290,959,780
- Shares
- -2,838,632
- Change %
- -39%
- Price
- $102.50
- Shares after
- 4,372,852
- Date
- 14 Jul 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
BAKER BROS. ADVISORS LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Celcuity Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Footnote F2
Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
Footnote F3
Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Footnote F4
After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
SEC remarks
On July 14, 2026, Baker Bros. Advisors LP on behalf of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"), submitted written notice to Celcuity Inc. (the "Issuer") to set the beneficial ownership limitation (the "Maximum Percentage") with respect to 481,437 and 5,666,350 prefunded warrants to purchase common stock of the Issuer ("Common Stock") at an exercise price of $0.001 per share held by 667 and Life Sciences, respectively, at 9.99%. As a result of the transactions reported herein and the setting of the Maximum Percentage at 9.99%, the reporting persons no longer beneficially own greater than 10% of the Common Stock.